A daily pill can double survival time in patients with the world’s deadliest cancer, according to the results of a clinical trial that experts are saying is a gamechanger and one of the biggest breakthroughs in decades. To find out more about how daraxonrasib works and how life-changing it could be for patients, Madeleine Finlay speaks to Prof Naureen Starling, consultant medical oncologist at the Royal Marsden hospital. Help support our independent journalism at theguardian.com/sciencepod
Smart linkhttps://pc.st/e/47AwFuBQt0e
Official sitehttps://www.theguardian.com/science/series/science
Auto-openhttps://pc.st/e/47AwFuBQt0e?a
Add podcast to the siteEmbed Podcast







